Releases
MESO
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Mesoblast (MESO) stock and general news. This information may help you make smarter investment decisions.
About MESO
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.
More